£85.0m acquisition in London's Knowledge Quarter
9 May 2022
LEI: 213800RG7JNX7K8F7525
Life Science REIT plc
("Life Science REIT" or the "Company")
£85.0 million acquisition in London's Knowledge Quarter
Sixth transaction since IPO and second major asset in London
Life Science REIT (AIM: LABS), the real estate investment trust focused on UK life science properties, announces that, on 6 May 2022, it completed the acquisition of 7-11 Herbrand Street, an iconic Art Deco building close to University College Hospital and University College London in London's Knowledge Quarter, the area that includes Bloomsbury, King's Cross and St Pancras.
The purchase price of £85.0 million, excluding acquisition costs, was satisfied entirely in cash and reflects a net initial yield of 4.42% based on the underlying net passing rent of £59.85 per square foot. The entire building is currently let to Thought Machine, one of the UK's leading fintech companies, until October 2026.
The property, which currently comprises Grade A office space, totals a net internal area of 67,097 square feet on four floors with a partial basement, and represents an ideal opportunity for development as a major life science asset. It is situated in close proximity to a number of major academic institutions, healthcare organisations and innovative companies including University College London, University College Hospital, the Francis Crick Institute and the Oriel project (a future world leading eye hospital, research and education centre due to open in 2026). The property is well-located for access to Euston, King's Cross, St Pancras and Tottenham Court Road transport hubs with Russell Square tube station just 100 metres away.
Life Science REIT, with support from key advisers, has undertaken a feasibility study to determine the suitability for lab conversion. The study confirmed that the building has great potential and benefits from large floor to ceiling heights, structural slab and large, column-free floor plates.
Life Science REIT has now deployed more than £262 million of total capital since its IPO, representing c. 75% of the net proceeds raised at IPO.
Simon Farnsworth, Managing Director of Ironstone Asset Management Ltd, the Company's Investment Adviser, said:
"We are delighted to have secured such a major acquisition for the Company in London's Knowledge Quarter. The important location and prominent size of the asset, along with attractive physical characteristics such as a large floor to ceiling height, represent outstanding potential for conversion into a leading long-term life science property.
"The transaction represents further progress in the deployment of our IPO proceeds, which are now approximately 75% invested and I am pleased to report that the Company's near-term acquisition pipeline remains extremely attractive."
Savills and CBRE acted on behalf of the vendor, LabTech.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (as it forms part of retained EU law as defined in the European Union (Withdrawal) Act 2018).
FOR FURTHER INFORMATION, PLEASE CONTACT:
|
Ironstone Asset Management - Investment Adviser |
|
|
Simon Farnsworth |
via Buchanan below |
|
|
|
|
Panmure Gordon - Nominated Adviser and Joint Corporate Broker |
+44 20 7886 2500 |
|
Atholl Tweedie / Sapna Shah / Philip Shields / Chloe Ponsonby |
|
|
|
|
|
Jefferies International Limited - Joint Corporate Broker |
+44 20 7029 8000 |
|
Tom Yeadon / Andrew Morris / Oliver Nott |
|
|
|
|
|
Buchanan - Financial PR |
+44 20 7466 5000 |
|
Mark Court / Henry Wilson / Verity Parker LifeSciencereit@buchanan.uk.com |
|
Notes to editors
Life Science REIT plc is a property business focused solely on the UK's growing life science sector, specifically targeting opportunities in the "Golden Triangle" research and development hubs of Oxford, Cambridge and London St Pancras. The Company's intention is to become the property provider of choice for life science companies in the UK, whilst enabling shareholders to gain exposure to a specific growth sector.
The objective of the Company's investment policy is focused on capital growth, whilst also providing a growing level of income, by investing primarily in a diversified portfolio of properties that are leased, or intended to be leased, to tenants operating in the life science sector in the UK.
Life Science REIT joined the AIM market of the London Stock Exchange on 19 November 2021, having raised £350 million in its IPO. Its shares trade under the ticker LABS.
Further information is available at https://lifesciencereit.co.uk
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 5 minutes ago Ithaca Energy
- 42 minutes ago MING YANG SMART ENERGY GROUP LIMITED
- 2 hours ago Trekor Metals Limited
- 2 hours ago ECR Minerals
- 2 hours ago Zotefoams